CIK 0001661460
PSTX Poseida Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jan 8, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Signals
Open-market buys and sells at Poseida Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Mark J Gergen Executive Chairman sell | $284k 30,000 shares | -4% | - | |
| 0Weak | Mark J Gergen Executive Chairman sell | $278k 30,000 shares | -4% | - |
Transactions
The last 38 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 8, 2025 | Charles M Baum director | UTender of shares Common Stock | -78,600 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Harry J Leonhardt GC & Chief Compliance Officer | UTender of shares Common Stock | -223,640 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Cynthia Collins director | UTender of shares Common Stock | -58,950 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Rafael Amado director | UTender of shares Common Stock | -58,950 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | UTender of shares Common Stock | -636,726 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Luke Corning director | UTender of shares Common Stock | -58,950 | - | - | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Rafael Amado director | DDisposition to issuer Stock Option (Right to Buy)derivative | -55,200 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Charles M Baum director | DDisposition to issuer Stock Option (Right to Buy)derivative | -57,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Harry J Leonhardt GC & Chief Compliance Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -160,385 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Cynthia Collins director | DDisposition to issuer Stock Option (Right to Buy)derivative | -87,440 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -240,721 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Luke Corning director | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,833 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -48,115 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Harry J Leonhardt GC & Chief Compliance Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -137,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Luke Corning director | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,500 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Rafael Amado director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Charles M Baum director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Cynthia Collins director | DDisposition to issuer Stock Option (Right to Buy)derivative | -28,500 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Luke Corning director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Harry J Leonhardt GC & Chief Compliance Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -72,568 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Charles M Baum director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -75,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Cynthia Collins director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -342,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Harry J Leonhardt GC & Chief Compliance Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -125,283 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Cynthia Collins director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Luke Corning director | DDisposition to issuer Stock Option (Right to Buy)derivative | -27,350 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -518,500 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Harry J Leonhardt GC & Chief Compliance Officer | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -111,700 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -364,060 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 8, 2025 | Mark J Gergen President and CEO | DDisposition to issuer Employee Stock Option (Right to Buy)derivative | -172,600 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 2, 2025 | Mark J Gergen Executive Chairman | FTax withholding Common Stock | -23,313 | $9.60 | $224k | 630,726 | Jan 3, 2025 |
| Dec 10, 2024 | Mark J Gergen Executive Chairman | MOption exercise Common Stock10b5-1 | +30,000 | $2.78 | $83k | 681,291 | Dec 11, 2024 |
| Dec 10, 2024 | Mark J Gergen Executive Chairman | SOpen-market sale Common Stock10b5-1 | -30,000 | $9.46 | $284k | 651,291 | Dec 11, 2024 |
| Dec 10, 2024 | Mark J Gergen Executive Chairman | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 96,372 | Dec 11, 2024 |
| Nov 26, 2024 | Mark J Gergen Executive Chairman | MOption exercise Common Stock10b5-1 | +30,000 | $2.78 | $83k | 681,291 | Nov 27, 2024 |
| Nov 26, 2024 | Mark J Gergen Executive Chairman | SOpen-market sale Common Stock10b5-1 | -30,000 | $9.27 | $278k | 651,291 | Nov 27, 2024 |
| Nov 26, 2024 | Mark J Gergen Executive Chairman | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 126,372 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Rafael Amadoofficer, director
- Charles M Baumdirector
- Cynthia Collinsdirector
- Luke Corningdirector
- Mark J GergenPresident and CEO
- Harry J LeonhardtGC & Chief Compliance Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.